The MPM market is expanding due to increased asbestos exposure, enhanced diagnostic capabilities, and the development of targeted therapies. Leading companies like Bristol-Myers Squibb, Merck, and ImmunoGen are working on immunotherapies and combination treatments. These advancements are focused on improving patient outcomes and addressing the significant unmet needs in the management of malignant pleural mesothelioma.
Access Market Report: https://shorturl.at/Yg2cZ
Gefällt mir
Kommentar
Teilen
